All In Biotech

Drug Trial Radar · NCT00395460

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients

A Single-blind, Multicenter, Randomized, Phase III Study of the Efficacy and Safety of Gadavist (1.0 M) in Comparison With Magnevist (0.5 M) as Contrast Agent for Enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions in Chinese Patients

Last checked: Nov 20, 2026Latest source record: Jun 8, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 147 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

147

Actual

Start

Sep 2006

Primary completion

Apr 2007

Study completion Apr 2007

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Nov 3, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of brain or spine diseases in patients of Chinese origin.

Conditions

  • Central Nervous System Diseases

Interventions

  • Gadobutrol (Gadavist, Gadovist, BAY86-4875)Drug

    1,0M, intra venous injection at a dose of 0,1 ml/kg BW (= 0,1 mmol Gd/kg BW)

  • MagnevistDrug

    0,5M, intra venous injection at a dose of 0,2 ml/kg BW (= 0,1 mmol Gd/kg BW)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Contrast to Noise Ratio (CNR) Between Pre- and Post-contrast Magnetic Resonance Imaging (MRI) Scan of Central Nervous System (CNS) LesionsTime frame: Immediately before injection (pre-contrast) and 2-5 min after injection (post-contrast)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hosp.

    Beijing, China

  • Fudan University Huashan Hospital

    Shanghai, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • The 1st Affiliated Hosp of the 4th Military Med Uni

    Xi'an, Shaanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.